Arbutus Biopharma Files 8-K on Operations and Personnel

Ticker: ABUS · Form: 8-K · Filed: 2025-08-06T00:00:00.000Z

Sentiment: neutral

Topics: operations, personnel, filing

TL;DR

Arbutus Biopharma dropped an 8-K covering financials, ops, and exec changes. Check it out.

AI Summary

Arbutus Biopharma Corporation filed an 8-K on August 6, 2025, reporting on events as of August 4, 2025. The filing covers results of operations and financial condition, director and officer changes, other events, and financial statements. The company was formerly known as Tekmira Pharmaceuticals Corp.

Why It Matters

This 8-K filing provides updates on Arbutus Biopharma's operational and financial status, as well as any significant changes in its leadership or board of directors.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on operational and personnel matters, not indicating immediate financial distress or significant new risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Arbutus Biopharma Corporation?

The primary purpose is to report on the company's results of operations and financial condition, departure/election of directors or officers, other events, and financial statements as of August 4, 2025.

When was this 8-K report filed with the SEC?

This 8-K report was filed on August 6, 2025.

What was Arbutus Biopharma Corporation's former name?

Arbutus Biopharma Corporation was formerly known as Tekmira Pharmaceuticals Corp.

What is the SIC code for Arbutus Biopharma Corporation?

The Standard Industrial Classification (SIC) code for Arbutus Biopharma Corporation is 2834, which corresponds to Pharmaceutical Preparations.

Where is Arbutus Biopharma Corporation headquartered?

Arbutus Biopharma Corporation's business and mailing address is 701 Veterans Circle, Warminster, PA 18974.

From the Filing

0001171843-25-005076.txt : 20250806 0001171843-25-005076.hdr.sgml : 20250806 20250806073130 ACCESSION NUMBER: 0001171843-25-005076 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250806 DATE AS OF CHANGE: 20250806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 251187463 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_080625.htm FORM 8-K Form 8-K False 0001447028 0001447028 2025-08-04 2025-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  August 4, 2025 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 2.02. Results of Operations and Financial Condition.   On August 6, 2025, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025 and certain other information. A copy of the press release is furn

View on Read The Filing